VRPX - Rasio utang marang kapitalisasi buku virpaxpharma.com

Virpax Pharmaceuticals develops opioid alternatives by engineering drug delivery methods via the skin and mucous membranes. The debt-to-capitalization ratio on GURU.Markets reflects current dynamics, where the indicator value stands at 0.00. This complements the PEP ecosystem, which utilizes an intranasal route to bypass the blood-brain barrier. However, internal conflicts and a shortage of funds during early-stage testing are draining the biotech's liquidity.

This indicator is calculated as the ratio of total liabilities to the book value of equity. It determines the business's dependence on external financing and the level of financial risk. For Virpax Pharmaceuticals (VRPX), such a capital structure is critical when developing non-opioid analgesics. A licensing scaling model allows the company to minimize borrowing while maintaining stability. The current leverage ratio based on book capital illustrates this balance between debt load and investment potential.